8-(4-acetamidophenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid | 508224-51-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 8-(4-acetamidophenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid
• 英文别名: 8-(4-acetylaminophenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid；8-(4-Acetamidophenyl)-1-cyclopropyl-9-methyl-4-oxoquinolizine-3-carboxylic acid
• CAS: 508224-51-9
• 化学式: C₂₂H₂₀N₂O₄
• 分子量: 376.412
• InChiKey: FXVGMFBOGZXGAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-(4-acetamidophenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid 在 potassium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 生成 potassium 8-(4-acetamidophenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylate
  参考文献：
  名称：

  2-PYRIDONE ANTIMICROBIAL COMPOSITIONS

  摘要：

  描述了一系列2-吡啶酮化合物，作为一种强效且选择性的新型II型拓扑异构酶抑制剂，具有广谱抗菌活性，其通用公式为（I）；其中R1，R2，X和Y在本文中定义。这类化合物可用于治疗由革兰氏阳性病原体、革兰氏阴性病原体或耐药菌株引起的感染。

  公开号：

  EP3034078A1
• 作为产物：
  描述：

  2-溴-4-氯吡啶 在 哌啶 、 manganese(IV) oxide 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 正丁基锂 、 硫酸 、 异丙基氯化镁 、 sodium hydride 、 caesium carbonate 、 溶剂黄146 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 32.5h， 生成 8-(4-acetamidophenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid
  参考文献：
  名称：

  2-PYRIDONE ANTIMICROBIAL COMPOSITIONS

  摘要：

  描述了一系列2-吡啶酮化合物，作为一种强效且选择性的新型II型拓扑异构酶抑制剂，具有广谱抗菌活性，其通用公式为（I）；其中R1，R2，X和Y在本文中定义。这类化合物可用于治疗由革兰氏阳性病原体、革兰氏阴性病原体或耐药菌株引起的感染。

  公开号：

  EP3034078A1

文献信息

• [EN] ANTIMICROBIAL 4-OXOQUINOLIZINES<br/>[FR] 4-OXOQUINOLIZINES ANTIMICROBIENNES
  申请人：EVOLVA SA

  公开号：WO2012104305A1

  公开（公告）日：2012-08-09

  This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

  这项发明提供了新颖的4-氧喹啉化合物及其用途，用于一系列广谱抗生素，不会产生对现有或新出现的抗生素类别的交叉耐药性。此外，这些新颖的4-氧喹啉化合物对CDC A类和B类病原体具有作用。该发明还提供了包含某些4-氧喹啉与亚抑菌浓度的多粘菌素B结合的药物组合物，用于对抗对喹诺酮、碳青霉烯和其他抗微生物药物产生耐药性的临床分离株。
• 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure
  申请人：SATO PHARMACEUTICAL CO., LTD.

  公开号：US20040229903A1

  公开（公告）日：2004-11-18

  The present invention provides a 4-oxoquinolizine antibacterial agent having a 2-pyridone skeleton as a partial structure and also having a strong antibacterial effect on gram-positive bacteria, gram-negative bacteria or anaerobic bacteria. The compound having the following formula (I) or a pharmaceutically acceptable salt thereof: 1 wherein: R 1 represents hydrogen atom or a carboxyl-protecting group, R 2 represents hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxyl group or hydroxyl group, R 3 represents phenyl group or an aromatic substituent selected from the group consisting of 5-membered and 6-membered heterocyclic groups and R 3 has a substituent selected from the group consisting of a hydrogen atom, a lower alkyl group, a lower alkoxyl group, a nitro group, a cyano group, an amino group, an acyl group, a carbamoyl group and a ureido group, and R 4 represents a hydrogen atom or a halogen atom.

  本发明提供了一种具有2-吡啶酮骨架作为部分结构并对革兰氏阳性菌、革兰氏阴性菌或厌氧菌具有强烈抗菌作用的4-氧喹啉类抗菌剂。该化合物具有以下式（I）或其药学上可接受的盐：1其中：R1代表氢原子或羧基保护基，R2代表氢原子、卤素原子、较低的烷基、较低的烷氧基或羟基，R3代表苯基或从5-成员和6-成员杂环基组成的芳香基取代基，且R3具有从氢原子、较低的烷基、较低的烷氧基、硝基、氰基、氨基、酰基、氨基甲酰基和尿素基组成的取代基，以及R4代表氢原子或卤素原子。
• ANTIMICROBIAL 4-OXOQUINOLIZINES
  申请人：Heim Jutta

  公开号：US20130252882A1

  公开（公告）日：2013-09-26

  This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

  该发明提供了新型的4-氧喹啉并化合物及其用途，适用于一系列广谱抗生素，不与现有或新出现的抗生素类别产生交叉耐药性。此外，新型的4-氧喹啉并化合物对CDC A和B类病原体也有用。该发明还提供了包含某些4-氧喹啉并化合物与亚抑制浓度的多粘菌素B的药物组合，用于对抗对喹诺酮、碳青霉烯和其他抗微生物药物产生耐药性的临床分离株。
• 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE
  申请人：Sato Pharmaceutical Co. Ltd.

  公开号：EP1437354A1

  公开（公告）日：2004-07-14

  The present invention provides a 4-oxoquinolizine antibacterial agent having a 2-pyridone skeleton as a partial structure and also having a strong antibacterial effect on gram-positive bacteria, gram-negative bacteria or anaerobic bacteria. The compound having the following formula (I) or a pharmaceutically acceptable salt thereof: wherein: R1 represents hydrogen atom or a carboxyl-protecting group, R2 represents hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxyl group or hydroxyl group, R3 represents phenyl group or an aromatic substituent selected from the group consisting of 5-membered and 6-membered heterocyclic groups and R3 has a substituent selected from the group consisting of a hydrogen atom, a lower alkyl group, a lower alkoxyl group, a nitro group, a cyano group, an amino group, an acyl group, a carbamoyl group and a ureido group, and R4 represents a hydrogen atom or a halogen atom.

  本发明提供了一种以 2-吡啶酮骨架为部分结构，同时对革兰氏阳性菌、革兰氏阴性菌或厌氧菌有较强抗菌作用的 4-氧代喹嗪类抗菌剂。具有下式（I）的化合物或其药学上可接受的盐： 其中 R1 代表氢原子或羧基保护基团、 R2 代表氢原子、卤素原子、低级烷基、低级烷氧基或羟基、 R3 代表苯基或选自 5 元和 6 元杂环基团的芳香取代基，且 R3 具有选自氢原子、低级烷基、低级烷氧基、硝基、氰基、氨基、酰基、氨基甲酰基和脲基的取代基，以及 R4 代表氢原子或卤素原子。
• Antimicrobial 4-oxoquinolizines
  申请人：Emergent Product Development Gaithersburg Inc.

  公开号：US10155021B2

  公开（公告）日：2018-12-18

  This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

  本发明提供了新型 4-oxoquinolizine 化合物及其在一系列广谱抗生素中的用途，这些抗生素对现有或新出现的抗生素类别没有交叉抗药性。此外，新型 4-oxoquinolizine 化合物还可用于抗 CDC A 类和 B 类病原体。本发明还提供了由某些 4-氧代喹嗪类化合物与亚抑制浓度的多粘菌素 B 组合而成的药物组合物，用于抗击对喹诺酮类、碳青霉烯类和其他抗菌剂耐药的临床分离菌。